PARP Inhibitor Biomarkers Market Size is valued at USD 897.8 Mn in 2023 and is predicted to reach USD 1,751.6 Mn by the year 2031 at a 8.8% CAGR during the forecast period for 2024-2031.
These biomarkers play a critical role in informing treatment decisions and identifying patients who are at the highest risk of benefiting from PARP inhibitor therapy. In order to detect these markers, genomic profiling or specific genetic assays are frequently employed. The growth of the PARP (poly-ADP ribose polymerase) inhibitor biomarkers market is attributed to several factors, including the increasing occurence of breast cancer, advancements in genetic technologies, and rising expenditures for oncology treatments. Research and development efforts aimed at novel therapies are expected to propel the global PARP inhibitor biomarkers market during the forecast period.
Their research suggests that combining chemotherapy with PARP inhibitors can effectively suppress the proliferation of cancer cells and induce their destruction. Consequently, the growing focus on cancer treatment research and development is anticipated to create lucrative opportunities for manufacturers to introduce new products and developments to the market. Furthermore, the expansion is attributed to the substantial rise in investments in PARP inhibitor biomarkers technologies throughout the region, accompanied by an increase in per capita income, which drives the greater adoption of diagnostic and therapeutic products. Government initiatives aimed at enhancing healthcare infrastructure further contribute to the anticipated regional growth.
The PARP Inhibitor Biomarkers market is segmented by product, services and application. As per the product, the market is segmented as kits and Assays. By services, the market is bifurcated into BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others. The application segment includes Breast Cancer, Ovarian Cancer, and Others.
The assay segment is poised to dominate the PARP Inhibitor Biomarkers market throughout the forecast period. This assay assesses the comparative specificity of PARP inhibitors and analyzes the levels of ADP-ribosylation by individual PARPs across different conditions. It serves as a valuable asset in research and development settings, facilitating the investigation of the effects of PARP inhibitors on cancer cells or the creation of novel assays for potential clinical use.
The breast cancer sector is anticipated to dominate the market. Breast cancer represents a prevalent cancer type among women, standing as the primary cause of cancer-related fatalities in females across 95% of nations. However, survival rates exhibit substantial variance, with a notable majority of fatalities occurring in low- and middle-income countries. While high-income nations have experienced marked declines in breast cancer mortality rates over recent decades, comparable progress has not been realized in low- and middle-income nations. This discrepancy in survival rates primarily stems from late-stage diagnoses, inadequate diagnostic and treatment resources, and the absence of breast cancer coverage under universal health schemes in these regions.
North America is expected to become the dominant area in the global PARP Inhibitor Biomarkers market. Healthcare professionals and patients in North America are increasingly recognizing the importance of biomarkers in personalized medicine and targeted therapy. This increased awareness translates into a rising demand for PARP inhibitor biomarkers in clinical settings, further propelling market growth across the region.
In summary, the anticipated significant market share of the North American PARP Inhibitor Biomarkers Market is underpinned by its advanced healthcare infrastructure, high cancer incidence, robust research and development landscape, regulatory support, and escalating awareness and adoption of biomarker-guided therapies. Additionally, APAC region dominance stems from an increasing focus on environmentally friendly building practices and a surge in the demand for sustainable construction solutions. Additionally, the growing adoption of devices featuring advanced capabilities in emerging economies like China, Japan, and India is projected to propel market expansion during the forecast period.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 897.8 Mn |
|
Revenue Forecast In 2031 |
USD 1,751.6 Mn |
|
Growth Rate CAGR |
CAGR of 8.8% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, Services and Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Myriad Genetics, Inc., AmbryGenetics, Thermo Fisher Scientific Inc., Illumina, Inc., CENTOGENE N.V., Amoy Diagnostics Co., Ltd.; Invitae Corporation, NeoGenomics Laboratories., QIAGEN, Agilent Technologies, Inc., F. Hoffmann-La Roche AG, Bio Rad Laboratories Inc., Exagen Inc., Genway Biotech, Inc., Svar Life Science AB, Siemens Healthcare GmbH, Other Market Players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global PARP Inhibitor Biomarkers Market Snapshot
Chapter 4. Global PARP Inhibitor Biomarkers Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Product Estimates & Trend Analysis
5.1. by Product & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Product:
5.2.1. Kits
5.2.2. Assays
Chapter 6. Market Segmentation 2: by Services Estimates & Trend Analysis
6.1. by Services & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Services:
6.2.1. BRCA 1&2 Testing
6.2.2. HRD Testing
Chapter 7. Market Segmentation 3: by Application Estimates & Trend Analysis
7.1. by Application & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
7.2.1. Breast Cancer
7.2.2. Ovarian Cancer
7.2.3. Others
Chapter 8. PARP Inhibitor Biomarkers Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Product, 2019-2031
8.1.2. North America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Services, 2019-2031
8.1.3. North America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.1.4. North America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.2. Europe
8.2.1. Europe PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Product, 2019-2031
8.2.2. Europe PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Services, 2019-2031
8.2.3. Europe PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.2.4. Europe PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.3. Asia Pacific
8.3.1. Asia Pacific PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Product, 2019-2031
8.3.2. Asia Pacific PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Services, 2019-2031
8.3.3. Asia-Pacific PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.3.4. Asia Pacific PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.4. Latin America
8.4.1. Latin America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Product, 2019-2031
8.4.2. Latin America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Services, 2019-2031
8.4.3. Latin America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.4.4. Latin America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Product, 2019-2031
8.5.2. Middle East & Africa PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Services, 2019-2031
8.5.3. Middle East & Africa PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.5.4. Middle East & Africa PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Myriad Genetics, Inc.
9.2.2. Ambry Genetics
9.2.3. Thermo Fisher Scientific, Inc.
9.2.4. Illumina, Inc.
9.2.5. CENTOGENE N.V.
9.2.6. Amoy Diagnostics Co., Ltd.
9.2.7. Invitae Corporation
9.2.8. NeoGenomics Laboratories.
9.2.9. QIAGEN
9.2.10. Agilent Technologies, Inc.
9.2.11. Other Prominent Players
PARP Inhibitor Biomarkers Market By Product
PARP Inhibitor Biomarkers Market By Services
PARP Inhibitor Biomarkers Market By Application
PARP Inhibitor Biomarkers Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
